Selective TYK2 Inhibitors for Reduced JAK-Family Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors lack high selectivity for TYK2 over other members of the JAK family, leading to undesirable side effects and a narrow therapeutic index in treating autoimmune diseases.
Innovation Solution
Development of compounds that selectively inhibit TYK2 by targeting specific structural features, such as aromatic or heteroaromatic rings fused with a 5-membered heteroaromatic ring, with optional substitutions, to achieve high potency and selectivity for TYK2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-JAK inhibitors or modestly selective inhibitors are used, then broad JAK family coverage is achieved, but selectivity for specific JAK members deteriorates leading to side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (substituted pyrimidine or pyridine rings with particular substituent patterns at positions 2, 4, and 6) that create localized interactions with TYK2's unique binding pocket. This enables the inhibitor to distinguish TYK2 from other JAK family members by exploiting local structural differences in the ATP binding site, thereby achieving high selectivity and reducing off-target side effects while maintaining therapeutic effectiveness.
2Reliability
If ATP site-directed inhibitors are used, then catalytic activity is blocked, but selectivity among JAK family members deteriorates due to high homology of the active site
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (substituted pyrimidine or pyridine rings with particular substituent patterns at positions 2, 4, and 6) that create localized interactions with TYK2's unique binding pocket. This enables the inhibitor to distinguish TYK2 from other JAK family members by exploiting local structural differences in the ATP binding site, thereby achieving high selectivity and reducing off-target side effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters of the inhibitor structure, including the type of heterocyclic core (pyrimidine vs. pyridine), the identity and position of substituents (halogens, alkyl groups, alkoxy groups), and the spatial arrangement of these substituents. These parameter variations allow optimization of the inhibitor's binding affinity and selectivity for TYK2 by tuning the molecular properties to match the specific structural features of TYK2's ATP binding site, thereby achieving both potent catalytic inhibition and high selectivity.
Data Source
AI summary
This disclosure relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2). The disclosure further provides methods of preparing the compounds of the disclosure, and methods for their therapeutic use.